N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.
Nuvec® is currently in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems.
Learn more
Watch our new video animation below to see Nuvec® in action:
Latest news and updates
Roundtable: What are the current investment trends in the pharmaceutical industry and how are they influencing the sector’s direction?
Pharma’s Almanac’s Q2 2024 roundtable ‘What are the current investment trends in the pharmaceutical industry and how are they influencing the sector’s direction?’ features a response from Nigel Theobald, CEO, N4 Pharma.Contributing to the discussion, [...]
Article: Are oral formulations of oligonucleotide therapeutics within reach?
Our latest article explores the challenges with targeting the gastrointestinal (GI) tract and outlines the current strategies aiming to unlock the potential of oral delivery for siRNA drugs targeted against GI diseases and cancers. We [...]
Share Spotlight: Biotech firm N4 Pharma is delivering cutting edge solutions to the UK
Shares Magazine shines a spotlight on N4 Pharma (N4P:AIM), revolutionising biotech with advanced delivery systems for nucleic acids in oncology, gene therapy, and vaccines. Our patented mesoporous silica nanoparticles and newly acquired lipid-peptide delivery platform [...]